BASTA JAMES is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $112K.
Profile
James Basta is the Executive Vice President and General Counsel of Intellia Therapeutics, Inc. (NTLA). In the 2026-01-07 SEC filing (CIK 0001792726), he is listed as EVP and General Counsel; no equity purchases or sales were reported in that filing. Intellia Therapeutics is a biotechnology company focused on CRISPR/Cas9-based gene-editing therapeutics.
Role
Insider
Notability
40/100
Board memberships
Intellia Therapeutics, Inc.
Awards & honors
Oversees corporate governance and legal affairs for Intellia Therapeutics
Leads regulatory compliance and intellectual property strategy
James Basta is the Executive Vice President and General Counsel of Intellia Therapeutics, Inc. (NTLA). In the 2026-01-07 SEC filing (CIK 0001792726), he is listed as EVP and General Counsel; no equity purchases or sales were reported in that filing. Intellia Therapeutics is a biotechnology company focused on CRISPR/Cas9-based gene-editing therapeutics.…
Has BASTA JAMES been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($112K) across all tracked filings.
Where can I see all of BASTA JAMES's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
